Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line
- 1 November 2018
- journal article
- research article
- Published by Elsevier in Leukemia Research
- Vol. 74, 1-9
Abstract
No abstract availableKeywords
Funding Information
- NIH (R01 AI081757, U19 A1063603, U01 GM094653, U01 AI084146)
- NIH (TL1 RR025772)
This publication has 50 references indexed in Scilit:
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic LeukemiaClinical Cancer Research, 2015
- mTOR Inhibition by Everolimus in Childhood Acute Lymphoblastic Leukemia Induces Caspase-Independent Cell DeathPLOS ONE, 2014
- Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levelsOncotarget, 2012
- mTOR: from growth signal integration to cancer, diabetes and ageingNature Reviews Molecular Cell Biology, 2010
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphomaLeukemia, 2010
- Role of Pten in leukemia stem cellsOncotarget, 2010
- Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in miceBlood, 2010
- Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathwaysLeukemia, 2009
- Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemiaBlood, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009